CompletedPhase 2NCT04098406

Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Clene Nanomedicine
Principal Investigator
Parvarthi Menon, PhD, MD, MBBS
Westmead Hospital
Intervention
CNM-Au8(drug)
Enrollment
45 enrolled
Eligibility
30-80 years · All sexes
Timeline
20192021

Study locations (2)

Collaborators

Clene Australia Pty Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04098406 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials